208 related articles for article (PubMed ID: 15928228)
1. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.
Taylor R; Taguchi K
Ann Fam Med; 2005; 3(3):242-7. PubMed ID: 15928228
[TBL] [Abstract][Full Text] [Related]
2. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial.
Kinney AY; Richards C; Vernon SW; Vogel VG
Prev Med; 1998; 27(5 Pt 1):713-9. PubMed ID: 9808803
[TBL] [Abstract][Full Text] [Related]
3. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
Layeequr Rahman R; Crawford S
Breast; 2009 Oct; 18(5):289-93. PubMed ID: 19716702
[TBL] [Abstract][Full Text] [Related]
5. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
Crowell EB; Jubelirer SJ
W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
8. Prescription of tamoxifen for breast cancer prevention by primary care physicians.
Armstrong K; Quistberg DA; Micco E; Domchek S; Guerra C
Arch Intern Med; 2006 Nov; 166(20):2260-5. PubMed ID: 17101945
[TBL] [Abstract][Full Text] [Related]
9. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
10. Women's views on chemoprevention of breast cancer: qualitative study.
Heisey R; Pimlott N; Clemons M; Cummings S; Drummond N
Can Fam Physician; 2006 May; 52(5):624-5. PubMed ID: 17327893
[TBL] [Abstract][Full Text] [Related]
11. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
[TBL] [Abstract][Full Text] [Related]
12. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
Brewster AM; Christo DK; Lai H; Helzlsouer K
Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
[TBL] [Abstract][Full Text] [Related]
14. Predicting compliance in a breast cancer prevention trial.
Maurice A; Howell A; Evans DG; O'Neil AC; Scobie S
Breast J; 2006; 12(5):446-50. PubMed ID: 16958964
[TBL] [Abstract][Full Text] [Related]
15. How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide.
McKay A; Martin W; Latosinsky S
Breast Cancer Res Treat; 2005 Nov; 94(2):153-9. PubMed ID: 16261414
[TBL] [Abstract][Full Text] [Related]
16. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
[TBL] [Abstract][Full Text] [Related]
17. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.
Hackshaw A; Roughton M; Forsyth S; Monson K; Reczko K; Sainsbury R; Baum M
J Clin Oncol; 2011 May; 29(13):1657-63. PubMed ID: 21422412
[TBL] [Abstract][Full Text] [Related]
18. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
[TBL] [Abstract][Full Text] [Related]
19. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
McKay A; Latosinsky S; Martin W
Cancer; 2005 Jan; 103(1):209-10. PubMed ID: 15540238
[No Abstract] [Full Text] [Related]
20. Breast cancer risk assessment and risk reduction.
Newman LA; Vogel VG
Surg Clin North Am; 2007 Apr; 87(2):307-16, vii-viii. PubMed ID: 17498528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
